This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
by Zacks Equity Research
Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.
Conatus (CNAT) Completes Enrollment in Phase II NASH Study
by Zacks Equity Research
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
by Zacks Equity Research
Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
by Zacks Equity Research
A low key week for the biotech sector with focus on regular pipeline updates.
Implied Volatility Surging for Conatus (CNAT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Conatus (CNAT) stock based on the movements in the options market lately.
Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
by Zacks Equity Research
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
Why Is Conatus (CNAT) Up 4.7% Since Last Earnings Report?
by Zacks Equity Research
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Conatus (CNAT) stock based on the movements in the options market lately.
Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
by Zacks Equity Research
Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.
Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Conatus (CNAT) delivered earnings and revenue surprises of 0.00% and -20.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock
by Zacks Equity Research
Conatus Pharmaceuticals (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock
by Zacks Equity Research
Conatus Pharmaceuticals (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.
Conatus (CNAT) Up 36.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally
by Zacks Equity Research
Conatus (CNAT) incurs narrower-than-expected loss in Q2. Sales miss estimates.
Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Conatus (CNAT) delivered earnings and revenue surprises of 25.00% and -3.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
On Conatus' (CNAT) second-quarter 2018 conference call, investor focus will remain on the company's progress with respect to its lead candidate, emricasan.
NASH Space in Focus as Galmed (GLMD) Posts Positive Data
by Ekta Bagri
Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.
Why Is Conatus Pharmaceuticals (CNAT) Up 4.1% Since Its Last Earnings Report?
by Zacks Equity Research
Conatus Pharmaceuticals (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates
by Zacks Equity Research
Conatus (CNAT) reports in-line loss in Q1 while revenues beat estimates. Moreover, the top line improves year over year.
What's in the Cards for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.
Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
by Zacks Equity Research
The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
Are Options Traders Betting on a Big Move in Conatus (CNAT) Stock?
by Zacks Equity Research
Investors in Conatus Pharmaceuticals (CNAT) need to pay close attention to the stock based on moves in the options market lately.
Conatus' Emricasan Fails in Phase II Study, Shares Sink
by Zacks Equity Research
Conatus Pharmaceuticals' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on liver transplant patients with fibrosis or cirrhosis.